DNAJC15 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9Y5T4 |
---|---|
Clone Names | 100405214 |
Gene ID | 29103 |
---|---|
Other Names | DnaJ homolog subfamily C member 15, Cell growth-inhibiting gene 22 protein, Methylation-controlled J protein, MCJ, DNAJC15, DNAJD1 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP13156c was selected from the Center region of DNAJC15. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | DNAJC15 |
---|---|
Synonyms | DNAJD1 |
Function | Negative regulator of the mitochondrial respiratory chain. Prevents mitochondrial hyperpolarization state and restricts mitochondrial generation of ATP (By similarity). Acts as an import component of the TIM23 translocase complex. Stimulates the ATPase activity of HSPA9. |
Cellular Location | Mitochondrion inner membrane; Single-pass membrane protein |
Tissue Location | Expressed at highest levels in heart, followed by liver and kidney. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
DNAJC15 is absent or down-regulated in many advanced cases of ovarian adenocarcinoma, due to hypermethylation and allelic loss. Loss of expression correlates with increased resistance to antineoplastic drugs, such as cisplatin.
References
Need, A.C., et al. Hum. Mol. Genet. 18(23):4650-4661(2009)Witham, J., et al. Int. J. Cancer 122(11):2641-2645(2008)Hatle, K.M., et al. Mol. Cell. Biol. 27(8):2952-2966(2007)Lindsey, J.C., et al. Int. J. Cancer 118(2):346-352(2006)Strathdee, G., et al. Carcinogenesis 25(5):693-701(2004)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.